- Trials with a EudraCT protocol (395)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
395 result(s) found for: pharmacogenetics.
Displaying page 14 of 20.
| EudraCT Number: 2018-000877-61 | Sponsor Protocol Number: LLC1518 | Start Date*: 2018-06-12 | |||||||||||
| Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
| Full Title: Activity and safety of front-line venetoclax and rituximab association (VeRiTAs) in young and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or disrupted TP53. A phase ... | |||||||||||||
| Medical condition: Chronic Lymphocytic Leukemia (CLL) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-003997-25 | Sponsor Protocol Number: MDS0519 | Start Date*: 2020-06-10 | ||||||||||||||||
| Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||
| Full Title: Prospective randomized study on the feasibility of allogeneic stem cell transplantation in higher-risk-myelodysplastic syndromes, performed upfront or preceded by azacitidine or conventional chemot... | ||||||||||||||||||
| Medical condition: Higher-risk-myelodysplastic syndromes | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-000392-33 | Sponsor Protocol Number: AML1718 | Start Date*: 2018-08-29 | |||||||||||
| Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
| Full Title: A Safety Run-in and phase II, open-label, multicentre, study investigating safety, tolerability and effectiveness of Venetoclax add in combination at Fludarabine, Cytarabine and Idarubicine in ind... | |||||||||||||
| Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004003-46 | Sponsor Protocol Number: RealMM | Start Date*: 2018-09-05 | |||||||||||
| Sponsor Name:DIPARTIMENTO DI BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE-UNIVERISITÀ DI TORINO | |||||||||||||
| Full Title: A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT... | |||||||||||||
| Medical condition: Newly diagnosed MM patients = 65 years old or ineligible for autologous stem cell transplant | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000923-37 | Sponsor Protocol Number: TriComB | Start Date*: 2021-08-04 | |||||||||||
| Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST | |||||||||||||
| Full Title: A phase 1/2 study exploring the safety and activity of Trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients. | |||||||||||||
| Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001543-94 | Sponsor Protocol Number: AML2020 | Start Date*: 2020-12-15 | ||||||||||||||||
| Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||
| Full Title: Tagraxofusp in Patients with CD123+ or with Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia. | ||||||||||||||||||
| Medical condition: Acute Myeloid Leukemia CD123 + or with BPDCN immunophenotype | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2015-000684-13 | Sponsor Protocol Number: LLC1215 | Start Date*: 2015-09-18 | |||||||||||
| Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
| Full Title: A Phase II study of the combination of Ofatumumab and Ibrutinib followed by allogeneic bone marrow transplant or consolidation for pretreated high risk patients with Chronic Lymphocytic Leukemia | |||||||||||||
| Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-002055-10 | Sponsor Protocol Number: PURE-01 | Start Date*: 2020-07-06 |
| Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori | ||
| Full Title: PURE-01 – An open label, single-arm, phase 2 study of neoadjuvant pembrolizumab (MK-3475) before cystectomy for patients with muscle-invasive urothelial bladder cancer. | ||
| Medical condition: muscle-invasive urothelial bladder cancer | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) IT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-000472-40 | Sponsor Protocol Number: CN138-169 | Start Date*: 2005-08-10 |
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||
| Full Title: A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy w... | ||
| Medical condition: Schizophrenia | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) HU (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) BE (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-002793-23 | Sponsor Protocol Number: AI444-042 | Start Date*: 2012-03-07 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Phase 3 Evaluation of Daclatasvir (BMS-790052) in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4 Revised Protocol Number ... | |||||||||||||
| Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) ES (Completed) IT (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-004691-44 | Sponsor Protocol Number: CA187-017 | Start Date*: 2009-04-21 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients Estudio Fase II doble ciego, aleat... | |||||||||||||
| Medical condition: Progressive or recurrent non-small cell lung cancer (NSCLC) after treatment with one to two lines of cytotoxic chemotherapy cáncer de pulmón no microcítico progresivo o recurrente tras tratamiento ... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003965-16 | Sponsor Protocol Number: CA209-063 | Start Date*: 2013-05-13 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Single-Arm Phase 2 Study of BMS-936558 in Subjects with Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens (CheckMate 063: CHE... | |||||||||||||
| Medical condition: Squamous cell non-small cell lung cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002608-15 | Sponsor Protocol Number: CC-10004-PSOR-025 | Start Date*: 2019-04-03 | |||||||||||
| Sponsor Name:Celgene Corporation | |||||||||||||
| Full Title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis | |||||||||||||
| Medical condition: MODERATE TO SEVERE GENITAL PSORIASIS | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) BE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-001514-42 | Sponsor Protocol Number: CA209-040 | Start Date*: 2015-01-29 | |||||||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
| Full Title: A Phase I-II Dose Escalation and Expansion Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibod... | |||||||||||||||||||||||
| Medical condition: Hepatocellular carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2006-001663-33 | Sponsor Protocol Number: MYCYC | Start Date*: 2007-12-06 |
| Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||
| Full Title: A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis | ||
| Medical condition: Anti neutrophil cytoplasmic antibody (ANCA) associated vasculitis | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) CZ (Completed) ES (Completed) SE (Completed) DE (Completed) IT (Completed) AT (Completed) FR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-001348-22 | Sponsor Protocol Number: FG-506-02-43 | Start Date*: 2005-07-21 | |||||||||||
| Sponsor Name:Astellas Pharma Europe Ltd | |||||||||||||
| Full Title: AN OPEN, RANDOMISED, MULTICENTRE CLINICAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF STEROID WITHDRAWAL WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND DACLIZUMAB AGAINST TACROLIMUS, MYCOPHENOLATE ... | |||||||||||||
| Medical condition: paediatric renal transplant patients | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) GB (Completed) SE (Completed) HU (Completed) BE (Completed) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-020744-35 | Sponsor Protocol Number: D4300C00002 | Start Date*: 2010-10-26 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Re... | |||||||||||||
| Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) DE (Completed) LV (Completed) LT (Completed) CZ (Completed) PT (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-005084-34 | Sponsor Protocol Number: CA182034 | Start Date*: 2009-02-02 | ||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
| Full Title: A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed... | ||||||||||||||||||
| Medical condition: Advanced Hepatocellular Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) ES (Completed) SE (Completed) FR (Completed) GR (Completed) BE (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2010-020140-36 | Sponsor Protocol Number: D4130C00005 | Start Date*: 2010-09-13 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepress... | |||||||||||||
| Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy. Complemento de un antidepresivo en pacientes con tras... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) DE (Completed) SK (Completed) FR (Completed) BG (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-005434-37 | Sponsor Protocol Number: IM101-174 | Start Date*: 2008-07-24 | |||||||||||
| Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
| Full Title: A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects with Rheumatoid Arth... | |||||||||||||
| Medical condition: RHEUMATOID ARTHRITIS, NOS | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) IE (Completed) HU (Completed) GB (Completed) BE (Completed) DE (Completed) NL (Completed) IT (Completed) AT (Prematurely Ended) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.